Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma

Neuro-Oncology

Volumn 10, Issue 4, 2008, Pages 617-623

  Phuphanich, Surasak ^a   Carson, Kathryn A ^b   Grossman, Stuart A ^b   Lesser, Glenn ^c   Olson, Jeffrey ^d   Mikkelsen, Tom ^e   Desideri, Serena ^b   Fisher, Joy D ^b,f  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY   (United States)

^e HENRY FORD HOSPITAL   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Anaplastic astrocytoma; Antiangiogenesis; Atrasentan; Endothelin receptor antagonist; Glioblastoma multiforme; Malignant glioma

Indexed keywords

ATRASENTAN; CARMUSTINE; DALTEPARIN; IRINOTECAN; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT; PYRROLIDINE DERIVATIVE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC RHINITIS; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GLIOBLASTOMA; HEADACHE; HUMAN; HYPOCALCEMIA; HYPOXIA; LEUKOCYTE COUNT; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUTROPHIL COUNT; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; RECURRENT CANCER; RHINITIS; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT OUTCOME; TUMOR REGRESSION; VOMITING; WEIGHT GAIN; XEROSTOMIA; BRAIN TUMOR; CASE REPORT; GLIOMA; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLIOMA; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PYRROLIDINES;

EID: 54049094871     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2008-013     Document Type: Article

References (30)

1. Central Brain Tumor Registry of the United States. Statistical report: primary brain tumors in the United States, 1998-2002. 2005 -2006.
2. Hoffman S, Propp JM, McCarthy BJ. Temporal trends in incidence of primary brain tumors in the United States, 1985 - 1999. Neuro-Oncology. 2006;8:27-37.
3. Levin VA, Leibel SA, Gutin PH. Neoplasms of the central nervous system In DeVita VT Jr, Hellman S, Rosenberg SA (eds), Cancer: Principles and Practice of Oncology, 6th Ed. Philadelphia: Lippincott Williams & Wilkes. 2001;2100-2160.
4. DeAngelis LM, Burger PC, Green SB, Cairncross JG. Malignant glioma: who benefits from adjuvant chemotherapy? Ann Neurol. 1998;44:691 - 695.
5. Stupp R, Mason WP, van den Bent, MJ, et al. European Organization for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glio- blastoma. N Engl J Med 2005;352(10):987-996.
6. Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980;303:1323 - 1329.
7. Levin VA, Kabra P. Effectiveness of the nitrosoureas as a function of their lipid solubility in the chemotherapy of experimental rat brain tumors. Cancer Chemother Rep. 1974;58:787 -792.
8. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999;17:2572 -2578.
9. Yung WK, Albright RE, Olson J, et al. A phase II study of temozolo- mide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83:588-593.
10. Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Natl Rev Cancer. 2003;3:110 - 116.
11. Opgenorth TJ, Adler AL, Calzadilla SV, et al. Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J Pharmacol Exp Ther. 1996;276:473 -481.
12. Remuzzi G, Perico N, Benigni A. New therapeutics that antagonize endothelin: promises and frustrations. Natl Rev Drug Discov. 2002;1:986 - 1 001.
13. Zonnenberg BA, Groenewegen G, Janus TJ, et al. Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer. Clin Cancer Res. 2003;9:2965 - 2972.
14. Wu-Wong JR, Chiou W, Magnuson SR, Bianchi BR, Lin CW. Human astrocytoma U138MG cells express predominantly type-A endothelin receptor. Biochim Biophys Acta. 1996;1311:155- 163.
15. Harland SP, Kuc RE, Pickard JD, Davenport AP. Characterization of endothelin receptors in human brain cortex, gliomas, and menin- giomas. J Cardiovasc Pharmacol. 1995;26(suppl 3): S408 - S411.
16. Tsutsumi K, Niwa M, Kitagawa N, et al. Enhanced expression of an endothelin ETA receptor in capillaries from human glioblastoma: a quantitative receptor autoradiographic analysis using a radiolumino- graphic imaging plate system. J Neurochem. 1994;63:2240-2247.
17. Stiles JD, Ostrow PT, Balos LL, et al. Correlation of endothelin-1 and transforming growth factor beta 1 with malignancy and vascularity in human gliomas. J Neuropathol Exp Neurol. 1997;56:435 -439.
18. Grossman SA, Fisher JD, Piantadosi S, Brem H. The new approaches to brain tumor therapy (NABTT) CNS consortium: organization, objectives, and activities. Cancer Control. 1998;5:107 - 114.
19. Grossman SA, Alavi JB, Supko JG, et al. Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas. Neuro-Oncology. 2005;7:32 -40.
20. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. 1958;53:457 -481.
21. Ryan CW, Vogelzang NJ, Vokes EE, et al. Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies. Clin Cancer Res. 2004;10:4406-4411.
22. Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone- refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol. 2003;21:679-689.
23. Sutsch G, Kiowski W, Yan XW, et al. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation. 1998;98:2262 -2268.
24. Study Report M96-435. A phase I, double-blind, placebo-controlled, multiple dose study of the safety and tolerability of ABT-627. Abbott Laboratories, Chicago, IL, USA; 1998.
25. Verhaar MC, Grahn AY, Van Weerdt AW, et al. Pharmacokinetics and pharmacodynamic effects of ABT-627, an oral ETA selective endothe- lin antagonist, in humans. Br J Clin Pharmacol. 2000;49:562 -573.
26. Dingemanse J, Clozel M, van Giersbergen PL. Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjects. Br J Clin Pharmacol. 2002;53:355 -362.
27. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan hypertension investigators. N Engl J Med. 1998;338:784-790.
28. Battistini B, Chailler P, D'Orleans-Juste P, Briere N, Sirois P. Growth regulatory properties of endothelins. Peptides. 1993;14:385 - 399.
29. Spinella F, Rosano L, Di Castro V, Natali PG, Bagnato A, Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia- inducible factor-1alpha in ovarian carcinoma cells. J Biol Chem. 2002;277:27850 - 27855.
30. Gupta RA, Tejada LV, Tong BJ, et al. Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res. 2003;63:906-911.